Lanadelumab exposure during steady state: achievement of effective concentrations in patients in the help study

In the HELP Study (NCT02586805), treatment with lanadelumab (a monoclonal antibody inhibitor of plasma kallirein) 150 mg q4wks, 300 mg q4wks, or 300 mg q2wks significantly decreased attack rates over 26 weeks. We evaluated the relationship between lanadelumab exposure and efficacy during steady state (days 70-182) among the 3 dose groups.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: B. Zuraw, M. Cicardi, J. Jacobs, H. Longhurst, P. Lu, M. Manning, M. Shennak, D. Soteres, Y. Wang, R. Zaragoza-Urdaz Tags: P170 Source Type: research